Work

195eP Real-world safety of ALK inhibitors in non-small cell lung cancer patients: A FAERS disproportionality analysis

Year: 2026

Type: article

Abstract: ALK inhibitors (ALKi) are a vital component for the management of non-small cell lung cancer (NSCLC) and have prolonged progression-free survival, although they are associated with distinct and evolving toxicity profiles. Given prolonged ALK-targeted therapy in clinical practice, real-world safety assessments are essential to characterize comparative adverse event reporting beyond clinical trials.

Source: ESMO Open

DOI: 10.1016/j.esmoop.2026.106502

Authors: A.I. Draghici, D.A. Urdea, S. Elrashidy, Y. Shhab, I. Tarabasanu-Mihaila, S. Aoun

Institutions: Iuliu Hațieganu University of Medicine and Pharmacy, Carol Davila University of Medicine and Pharmacy, Bahçeşehir University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,910